← Back to Search

Other

ANX007 for Age-Related Macular Degeneration (ARCHER Trial)

Phase 2
Waitlist Available
Research Sponsored by Annexon, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to month 18
Awards & highlights

ARCHER Trial Summary

This trial is testing a new drug to see if it can stop or slow the growth of vision loss from GA due to AMD. It will last about 19 months.

Who is the study for?
This trial is for people with a specific eye condition called geographic atrophy (GA) due to age-related macular degeneration. Participants must have GA lesions of certain sizes, clear vision within specified limits, and no other major eye diseases or treatments that could interfere with the study. Women must not be pregnant or breastfeeding and should use effective contraception.Check my eligibility
What is being tested?
The trial tests if ANX007 injections into the eye can slow down lesion growth in patients with GA secondary to AMD compared to sham injections. The study spans roughly 19 months and aims to inform further development of ANX007 for treating this eye condition.See study design
What are the potential side effects?
While specific side effects are not listed here, intravitreal injections like ANX007 may cause eye discomfort, redness, bleeding inside the eye (hemorrhage), increased pressure in the eye, cataracts, or infection.

ARCHER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to month 18
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to month 18 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
GA lesion growth rate
Secondary outcome measures
Best corrected visual acuity (BCVA)
Low-luminance BCVA (LL-BCVA)
Low-luminance visual acuity deficit (LL-VD)
+1 more

ARCHER Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: ANX007 Group 2Experimental Treatment1 Intervention
ANX007 administered every other month
Group II: ANX007 Group 1Experimental Treatment1 Intervention
ANX007 administered every month
Group III: Sham Group 4Placebo Group1 Intervention
Sham injection administered every other month
Group IV: Sham Group 3Placebo Group1 Intervention
Sham injection administered every month
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ANX007
2018
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

Annexon, Inc.Lead Sponsor
12 Previous Clinical Trials
528 Total Patients Enrolled
Clinical TrialsStudy DirectorAnnexon, Inc.
2,199 Previous Clinical Trials
888,232 Total Patients Enrolled

Media Library

ANX007 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04656561 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does ANX007 present any safety risks to individuals?

"Our team has assigned ANX007 a safety rating of 2, given that there is some substantiating evidence to suggest its protection but no studies yet confirming it's usefulness."

Answered by AI

Has recruitment begun for this experimental research initiative?

"Clinicaltrials.gov states that this trial, initially posted on February 26th 2021 and last updated July 1st 2022, is not actively searching for participants. However, there are 189 other promising studies currently recruiting volunteers."

Answered by AI

What is the scale of this clinical trial across medical facilities?

"Apart from the three previously mentioned sites, participants for this trial can be found in Site 35 Katy, Texas; Site 34 Burleson, California and Site 23 Pasadena, Florida. Additionally there are 46 other enrolment locations."

Answered by AI

Who else is applying?

What state do they live in?
Nevada
Other
Texas
Florida
How old are they?
18 - 65
65+
What site did they apply to?
Site 6
Site 11
Site 4
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
3+

Why did patients apply to this trial?

I am anxious to preserve the vision I have left. I have vision loss from age I guess it seems to get worse every week.
PatientReceived 2+ prior treatments
I am trying everything possible to halt the progression of my condition if not improve it. On the first page there was a Jacksonville. FL location but it did not appear on the list of potions to select.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

When would it start?
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
2021. "A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04656561.
All > Geographic Atrophy
~66 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top